文献速递糖尿病

目标范围内时间在糖尿病管理中的定位

Positioning time in range in diabetes management.
PubMed 文献 · Diabetologia · 2019-11-07

综述阐述持续葡萄糖监测(CGM)指标目标范围内时间(TIR)在糖尿病管理中的定位,指出TIR与HbA1c呈负相关且与并发症风险相关,但单独TIR不能反映低血糖频率或严重程度,强调需同时关注低于目标范围时间(TBR)及高于目标范围时间(TAR),并汇总了设置「范围内时间」目标的近期指导。

要点

  • TIR通常指血糖在3.9-10.0 mmol/l(妊娠期3.5-7.8 mmol/l)的时间比例。
  • 多数1型或2型糖尿病推荐TIR>70%、TBR<3.9 mmol/l<4%、TBR<3.0 mmol/l<1%。
  • TIR单独不能反映低血糖频率或严重程度,需结合TBR评估。

核心结论

  • TIR与HbA1c呈负相关且与并发症风险相关,但单独TIR不能反映低血糖频率或严重程度。
  • 讨论TIR时必须同时纳入低于目标范围时间(TBR)的量与严重程度,并由此推断高于目标范围时间(TAR)。

研究设计与样本

  • 综述,总结TIR与糖尿病并发症风险的关联、TIR与HbA1c的负相关以及设置「范围内时间」目标的近期指导。

主要发现

  • TIR与HbA1c呈负相关。
  • 新兴证据提示TIR与并发症风险相关。
  • 由于目标范围外血糖值分布偏斜,TIR单独是低血糖频率或严重程度的较差指标。

关键数值与推荐

  • TIR通常指血糖在3.9-10.0 mmol/l(妊娠期3.5-7.8 mmol/l)的时间比例。
  • 多数1型或2型糖尿病患者推荐TIR>70%、TBR<3.9 mmol/l<4%、TBR<3.0 mmol/l<1%。
  • 对老年人、高风险个体及25岁以下者采用较不严格的目标。
  • 血糖目标应个体化。

临床怎么用

  • 对选择使用CGM技术的个体,TIR常成为患者与医疗专业人员预期对话的一部分。
  • 共识建议已产生以促进标准化TIR目标的采用。
  • 在讨论TIR时应同时评估TBR的量与严重程度,并推断TAR。
  • 血糖目标应个体化,尤其在CGM个人使用及其数据解读时。

局限性

  • TIR单独是低血糖频率或严重程度的较差指标,因目标范围外血糖值分布偏斜。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent upswings in the use of continuous glucose monitoring (CGM) technologies have given people with diabetes and healthcare professionals unprecedented access to a range of new indicators of glucose control. Some of these metrics are useful research tools and others have been welcomed by patient groups for providing insights into the quality of glucose control not captured by conventional laboratory testing. Among the latter, time in range (TIR) is an intuitive metric that denotes the proportion of time that a person's glucose level is within a desired target range (usually 3.9-10.0 mmol/l [3.5-7.8 mmol/l in pregnancy]). For individuals choosing to use CGM technology, TIR is now often part of the expected conversation between patient and healthcare professional, and consensus recommendations have recently been produced to facilitate the adoption of standardised TIR targets. At a regulatory level, emerging evidence linking TIR to risk of complications may see TIR being more widely accepted as a valid endpoint in future clinical trials. However, given the skewed distribution of possible glucose values outside of the target range, TIR (on its own) is a poor indicator of the frequency or severity of hypoglycaemia. Here, the state-of-the-art linking TIR with complications risk in diabetes and the inverse association between TIR and HbA1c are reviewed. Moreover, the importance of including the amount and severity of time below range (TBR) in any discussions around TIR and, by inference, time above range (TAR) is discussed. This review also summarises recent guidance in setting 'time in ranges' goals for individuals with diabetes who wish to make use of these metrics. For most people with type 1 or type 2 diabetes, a TIR >70%, a TBR <3.9 mmol/l of <4%, and a TBR <3.0 mmol/l of <1% are recommended targets, with less stringent targets for older or high-risk individuals and for those under 25 years of age. As always though, glycaemic targets should be individualised and rarely is that more applicable than in the personal use of CGM and the data it provides.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Advani A. Positioning time in range in diabetes management. Diabetologia. 2019. PMID: 31701199. doi:10.1007/s00125-019-05027-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。